Results 41 to 50 of about 350 (116)

Anti‐ICOSL New Antigen Receptor Domains Inhibit T Cell Proliferation and Reduce the Development of Inflammation in the Collagen‐Induced Mouse Model of Rheumatoid Arthritis

Journal of Immunology Research, Volume 2018, Issue 1, 2018., 2018
Lymphocyte costimulation plays a central role in immunology, inflammation, and immunotherapy. The inducible T cell costimulator (ICOS) is expressed on T cells following peptide: MHC engagement with CD28 costimulation. The interaction of ICOS with its sole ligand, the inducible T cell costimulatory ligand (ICOSL; also known as B7‐related protein‐1 ...
Ronan O’Dwyer, Marina Kovaleva, Jiquan Zhang, John Steven, Emma Cummins, Deborah Luxenberg, Alfredo Darmanin-Sheehan, Miguel F. Carvalho, Matthew Whitters, Kenneth Saunders, Caroline J. Barelle, Ilaria Roato   +11 more
wiley   +1 more source

Human TNF cytokine neutralization with a vNAR fromHeterodontus franciscishark: A potential therapeutic use [PDF]

mAbs, 2013
The therapeutic use of single domain antibodies (sdAbs) is a promising new approach because these small antibodies maintain antigen recognition and neutralization capacity, have thermal and chemical stability and have good solubility. In this study, using phage display technology, we isolated a variable domain of a IgNAR (vNAR) from a Heterodontus ...
Tanya, Camacho-Villegas, Teresa, Mata-Gonzalez, Jorge, Paniagua-Solis, Edna, Sanchez, Alexei, Licea   +4 more
openaire   +2 more sources

Escherichia coli surface display for the selection of nanobodies

Microbial Biotechnology, Volume 10, Issue 6, Page 1468-1484, November 2017., 2017
Libraries of VHH genes encoding nanobodies have been traditionally cloned in phage display or yeast display systems. This review briefly describes these conventional approaches and focuses on the distinct properties of an E. coli display system developed in our laboratory, which combines the benefits of both phage display and yeast display systems ...
Valencio Salema, Luis Ángel Fernández
wiley   +1 more source

Bamboo Shark as a Small Animal Model for Single Domain Antibody Production

Frontiers in Bioengineering and Biotechnology, 2021
The development of shark single domain antibodies (sdAbs) is hindered by the high cost and tediousness of large-sized shark farming. Here, we demonstrated white-spotted bamboo sharks (Chiloscyllium plagiosum) being cultivated commercially as a promising ...
Likun Wei, Meiniang Wang, Meiniang Wang, Haitao Xiang, Haitao Xiang, Haitao Xiang, Yuan Jiang, Jinhua Gong, Dan Su, M. A. R. Al Azad, Hongming Dong, Hongming Dong, Hongming Dong, Limin Feng, Jiajun Wu, Leo Lai Chan, Leo Lai Chan, Naibo Yang, Naibo Yang, Naibo Yang, Jiahai Shi, Jiahai Shi, Jiahai Shi, Jiahai Shi, Jiahai Shi   +24 more
doaj   +1 more source

Shark Antibody Variable Domains Rigidify Upon Affinity Maturation—Understanding the Potential of Shark Immunoglobulins as Therapeutics

Frontiers in Molecular Biosciences, 2021
Sharks and other cartilaginous fish are the phylogenetically oldest living organisms that have antibodies as part of their adaptive immune system.
Monica L. Fernández-Quintero, Clarissa A. Seidler, Patrick K. Quoika, Klaus R. Liedl   +3 more
doaj   +1 more source

Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies

Frontiers in Immunology, 2020
The B-cell receptor (BCR) is a key player of the adaptive immune system. It is a unique part of immunoglobulin (Ig) molecules expressed on the surface of B cells. In case of many B-cell lymphomas, the tumor cells express a tumor-specific and functionally
Arturo Macarrón Palacios, Julius Grzeschik, Lukas Deweid, Simon Krah, Stefan Zielonka, Thies Rösner, Matthias Peipp, Thomas Valerius, Harald Kolmar   +8 more
doaj   +1 more source

From Multi‐Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR‐T Cell Therapy

Advanced Science, Volume 12, Issue 20, May 29, 2025.
This review explores how multi‐omics, visualization technologies, and AI drive CAR‐T therapy from the micro to the macro level, from preclinical studies to clinical applications. The convergence of these approaches provides deeper insight into CAR‐T cell mechanisms, aids in structural optimization, and significantly enhances treatment efficacy and ...
Yuting Gong, Peng Fei, Yicheng Zhang, Yang Xu, Jia Wei   +4 more
wiley   +1 more source

Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development

Frontiers in Immunology, 2017
The management of chronic inflammatory diseases, such as inflammatory bowel disease, psoriasis, and rheumatoid arthritis has significantly improved over the last decade with the clinical availability of anti-TNF-α biologics.
Obinna C. Ubah, John Steven, Marina Kovaleva, Laura Ferguson, Charlotte Barelle, Andrew J. R. Porter, Andrew J. R. Porter, Caroline J. Barelle   +7 more
doaj   +1 more source

Single domain antibody: Development and application in biotechnology and biopharma

Immunological Reviews, Volume 328, Issue 1, Page 98-112, November 2024.
Summary Heavy‐chain antibodies (HCAbs) are a unique type of antibodies devoid of light chains, and comprised of two heavy chains‐only that recognize their cognate antigen by virtue of a single variable domain also referred to as VHH, single domain antibody (sdAb), or nanobody (Nb).
Ting Yu, Fang Zheng, Wenbo He, Serge Muyldermans, Yurong Wen   +4 more
wiley   +1 more source

VNARs: An Ancient and Unique Repertoire of Molecules That Deliver Small, Soluble, Stable and High Affinity Binders of Proteins

Antibodies, 2015
At 420 million years, the variable domain of New Antigen Receptors or VNARs are undoubtedly the oldest (and smallest) antigen binding single domains identified in the vertebrate kingdom.
Caroline Barelle, Andy Porter
doaj   +1 more source